MVMarie Vibeke Vestergaard

Marie Vibeke Vestergaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie Vibeke Vestergaard has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Tine Jess

    Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark

    5 shared publications
  • Tine Jess

    Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

    4 shared publications
  • Aleksejs Sazonovs

    Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

    3 shared publications
  • Lone Larsen

    Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark

    3 shared publications
  • Anne Krogh Nøhr

    Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

    2 shared publications
  • Henrik Krarup

    Department of Molecular Diagnostics, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

    2 shared publications

Latest Publications

  • Reply

    by Marie Vibeke Vestergaard, Lone Larsen, Tine Jess

  • Open Access

    Genetic Risk of Inflammatory Bowel Disease Is Associated With Disease Course Severity

    by Marie Vibeke Vestergaard, Kristine Højgaard Allin, Anne Krogh Nøhr, Jesus Vicente Torresano Lominchar, Heidi Søgaard Christensen, Henrik Krarup, Kaspar René Nielsen, Henrik Albæk Jacobsen, Jonas Bybjerg-Grauholm, Marie Bækvad-Hansen, et al.


  • Open Access

    Multimodal analysis disentangles the genetic and microbial associations between inflammatory bowel disease and other immune-mediated diseases across a harmonized population framework

    by Marie Vibeke Vestergaard, Alonzo Alfaro-Núñez, Aleksejs Sazonovs, Georgios Athanasiadis, Tine Jess

    Immune-mediated inflammatory diseases (IMID) are chronic conditions with a well-established multifaceted association with the gastrointestinal diseases Crohn’s disease (CD) and ulcerative colitis (UC), commonly known as inflammatory bowel disease (IBD). In this study, we leverage Danish nationwide pedigree and health data, genome-wide association studies, and fecal microbiota data to characterize the association between IBD and other IMIDs and disentangle genetic and environmental contributions. We show that CD and UC have distinct patterns of correlations with other IMIDs within families. By evaluating genetic and gut microbial correlations, we highlight a UC microbiota-linked correlation with multiple sclerosis and systemic lupus erythematosus despite a negative genetic correlation, suggesting a key role for environmental factors. In contrast, we find consistent genetic and microbial convergence between both IBD subtypes and rheumatoid arthritis, whereas genetic factors mainly drive the correlation with psoriasis. Thus, our findings uncover heterogeneity in shared etiological pathways across immune diseases, underscoring the need for stratified approaches to diagnosing and treating IBD.


  • Open Access

    Fecal Microbiome Reflects Disease State and Prognosis in Inflammatory Bowel Disease in an Adult Population-Based Inception Cohort

    by Simen Hyll Hansen, Maria Gjerstad Maseng, Olle Grännö, Marie V Vestergaard, Corinna Bang, Bjørn C Olsen, Charlotte Lund, Christine Olbjørn, Emma E Løvlund, Florin B Vikskjold, et al.

    Introduction: We aimed to determine the diagnostic and prognostic potential of baseline microbiome profiling in inflammatory bowel disease (IBD). Methods: Participants with ulcerative colitis (UC), Crohn’s disease (CD), suspected IBD, and non-IBD symptomatic controls were included in the prospective population-based cohort Inflammatory Bowel Disease in South-Eastern Norway III (third iteration) based on suspicion of IBD. The participants donated fecal samples that were analyzed with 16S rRNA sequencing. Disease course severity was evaluated at the 1-year follow-up. A stringent statistical consensus approach for differential abundance analysis with 3 different tools was applied, together with machine learning modeling. Results: A total of 1404 individuals were included, where n = 1229 samples from adults were used in the main analyses (n = 658 UC, n = 324 CD, n = 36 IBD-U, n = 67 suspected IBD, and n = 144 non-IBD symptomatic controls). Microbiome profiles were compared with biochemical markers in machine learning models to differentiate IBD from non-IBD symptomatic controls (area under the receiver operating curve [AUC] 0.75-0.79). For UC vs controls, integrating microbiome data with biochemical markers like fecal calprotectin mildly improved classification (AUC 0.83 to 0.86, P < .0001). Extensive differences in microbiome composition between UC and CD were identified, which could be quantified as an index of differentially abundant genera. This index was validated across published datasets from 3 continents. The UC-CD index discriminated between ileal and colonic CD (linear regression, P = .008) and between colonic CD and UC (P = .005), suggesting a location-dependent gradient. Microbiome profiles outperformed biochemical markers in predicting a severe disease course in UC (AUC 0.72 vs 0.65, P < .0001), even in those with a mild disease at baseline (AUC 0.66 vs 0.59, P < .0001). Conclusions: Fecal microbiome profiling at baseline held limited potential to diagnose IBD from non-IBD compared with standard-of-care. However, microbiome shows promise for predicting future disease courses in UC.


  • Open Access

    HLA-DRB1*01:03 and Severe Ulcerative Colitis

    by Marie Vibeke Vestergaard, Anne Krogh Nøhr, Kristine Højgaard Allin, Henrik Krarup, Lone Larsen, Aleksejs Sazonovs, Tine Jess

    Ulcerative colitis is a chronic, immune-mediated disease with increasing incidence.1 There is a clinical need to identify biomarkers of severe disease to capture subgroups requiring intensified monitoring and treatment to avoid repeat hospitalizations and surgical procedures.2 This study aimed to identify biomarkers by conducting a Danish nationwide genome-wide association study (GWAS) on severe vs less severe ulcerative colitis.


  • Open Access

    Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein profiles in inflammatory bowel disease

    by Nathan Constantine-Cooke, Marie Vibeke Vestergaard, Nikolas Plevris, Karla Monterrubio-Gómez, Clara Ramos Belinchón, Solomon Ong, Alexander T. Elford, Beatriz Gros, Aleksejs Sazonovs, Gareth-Rhys Jones, et al.

    Background: Crohn’s disease (CD) and ulcerative colitis (UC) are highly heterogeneous, dynamic and unpredictable, with a marked disconnect between symptoms and intestinal inflammation. Objective: We aimed to describe latent disease heterogeneity in IBD by identifying longitudinal faecal calprotectin (FC) and CRP patterns. Design: In this longitudinal study, patient-level measurements of FC and CRP in two European cohorts were modelled. Latent class mixed models were used to cluster individuals with similar longitudinal profiles. Associations between cluster assignment and baseline characteristics were quantified using multinomial logistic regression. Differences in advanced therapy use across clusters were explored. Finally, we considered the overlap between FC and CRP clusters. Results: We included 1036 patients in the FC discovery analysis (Lothian) with a total of 10545 FC observations (median 9 per subject, IQR 6–13), and 7880 patients in the replication (Denmark). The CRP discovery analysis consisted of 1838 patients with 49364 measurements (median 20 per subject; IQR 10–36), with 10041 patients in the replication cohort. Eight distinct clusters of inflammatory behaviour over time were identified in the FC and CRP analysis. Similar patterns were observed in the replication cohort. The clusters included rapid remitters, delayed remitters, remitting-relapsing disease, and non-remitters The highest use of early advanced therapy was in the group with the lowest overall inflammation. There was broadly poor agreement between FC and CRP cluster assignment. Conclusion: Distinct patterns of inflammatory behaviour over time are evident in patients with IBD. These data pave the way for a deeper understanding of disease heterogeneity in IBD.


  • Open Access

    Genetic risk of inflammatory bowel disease is associated with disease course severity

    by Marie Vibeke Vestergaard, Kristine Højgaard Allin, Anne Krogh Noehr, Jesus Vicente Torresano Lominchar, Heidi Søgaard Christensen, Henrik Krarup, Kaspar René Nielsen, Henrik Albæk Jacobsen, Jonas Bybjerg-Grauholm, Marie Baekvad-Hansen, et al.

    Background and aims: Genetic susceptibility to inflammatory bowel disease (IBD) has been widely studied, whereas the genetic contribution to disease progression over time remains relatively under-investigated. In a Danish nationwide cohort, we aimed to explore if genetic susceptibility to IBD is associated with disease severity. Methods: We estimated polygenic scores (PGS) for IBD susceptibility for 3,732 patients with Crohn’s disease (CD), 4,535 patients with ulcerative colitis (UC), and 9,469 controls, and investigated their association with disease outcomes, including inflammatory markers, hospitalizations, major surgeries, and medication use. A composite severity outcome was defined based on the first three years following diagnosis. Lastly, we evaluated disease extent as a possible mediator of the association. Results: Increased susceptibility PGS was associated with higher fecal calprotectin and C-reactive protein levels, and decreased hemoglobin levels. When comparing the highest versus lowest PGS quintile, we observed a hazard ratio (HR) for major surgery of 2.74 ( P =7.19×10 -18 ) in patients with CD and of 2.04 ( P =4.36×10 -7 ) in UC. Patients with severe disease had higher susceptibility PGS than patients with less severe disease (CD: OR=1.25, P =3.36×10 -9 ; UC: OR=1.33, P =1.40×10 -15 per SD increase in PGS). Additionally, PGS was associated with a higher need for corticosteroids, immunomodulators, and biologic therapies. Adjusting for disease extent reduced the estimated associations for CD but had little impact on observed associations for UC. Conclusion: Patients with higher genetic burden for developing IBD also experience a more severe disease course. For patients with CD this link was largely mediated by disease extent, however, this was not the case for UC, which suggests a shared genetic architecture between disease susceptibility and severity.


  • Open Access

    Risk of Inflammatory Bowel Disease Following Hospitalisation with Infectious Mononucleosis: A Danish Nationwide Cohort Study (1977-2021)

    by Anthony Ebert, Shania Harper, Marie V. Vestergaard, Wayne Mitchell, Tine Jess, Rahma Elmahdi

    Background Infectious mononucleosis (IM) is a largely self-limiting syndrome mainly affecting adolescents and young adults but can present as a more severe disease requiring hospitalisation. The infectious agent most commonly causing IM, Epstein-Barr virus (EBV) has been associated with the development of several immune-mediated and inflammatory diseases. Objective To investigate the risk of inflammatory bowel disease (IBD) following hospitalisation with severe IM. Methods Danish nationwide registries were used to identify severe IM patients and sex-, age- and municipality-matched non-IM hospitalised controls, from 1st January 1977 to 31st December 2022. We undertook Cox regression modelling to calculate the hazards (HR) and 95% CI of IBD diagnosis, including Crohn’s disease (CD) and ulcerative colitis (UC). Analyses were stratified by sex and age at IM hospitalisation. Results We identified 39,684 patients with severe IM who were sex-, age-, and municipality-matched to 396,840 non-IM hospitalised controls. Severe IM was significantly associated with the development of IBD (HR:1.35; 95% CI: 1.22-1.49) and this was seen particularly in CD (HR: 1.56; 95% CI: 1.34-1.83) and to a lesser extent in UC (HR: 1.23; 95% CI: 1.08-1.40). Sex at severe IM diagnosis was not found to be a significant modifier to the risk of IBD development with risk increased in both females (HR: 1.36; 95% CI: 1.20-1.55) and males (HR: 1.34; 95% CI: 1.17-1.54). Only those receiving a severe IM diagnosis at 10-16 years (HR: 1.42; 95% CI:1.22-1.64) or 17-29 years (HR: 1.34; 95% CI:1.15-1.56) were at increased risk of IBD development. Conclusion This study demonstrated an association between IM hospitalisation and later IBD development, indicating an association between severe EBV disease and IBD development. Further exploration of factors contributing to IBD susceptibility following EBV infection is warranted.

  • Open Access

    Gut microbiota signatures in inflammatory bowel disease

    by Marie Vibeke Vestergaard, Kristine H. Allin, Carsten Eriksen, Oliwia Zakerska‐Banaszak, Ramesh P. Arasaradnam, Mohammad T. Alam, Karsten Kristiansen, Susanne Brix, Tine Jess

    Background: Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), affect millions of people worldwide with increasing incidence.Objectives: Several studies have shown a link between gut microbiota composition and IBD, but results are often limited by small sample sizes. We aimed to re‐analyze publicly available fecal microbiota data from IBD patients.Methods: We extracted original fecal 16S rRNA amplicon sequencing data from 45 cohorts of IBD patients and healthy individuals using the BioProject database at the National Center for Biotechnology Information. Unlike previous meta‐analyses, we merged all study cohorts into a single dataset, including sex, age, geography, and disease information, based on which microbiota signatures were analyzed, while accounting for varying technical platforms.Results: Among 2518 individuals in the combined dataset, we discovered a hitherto unseen number of genera associated with IBD. A total of 77 genera associated with CD, of which 38 were novel associations, and a total of 64 genera associated with UC, of which 28 represented novel associations. Signatures were robust across different technical platforms and geographic locations. Reduced alpha diversity in IBD compared to healthy individuals, in CD compared to UC, and altered microbiota composition (beta diversity) in UC and especially in CD as compared to healthy individuals were found.Conclusions: Combining original microbiota data from 45 cohorts, we identified a hitherto unseen large number of genera associated with IBD. Identification of microbiota features robustly associated with CD and UC may pave the way for the identification of new treatment targets.